Whitehawk expands ADC pipeline with option for five new programs using CPT113 linker-payload

Filed May 21, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• medium

  Whitehawk signed option agreement with Hangzhou DAC Biotechnology for linker-payload CPT113, enabling up to five additional antibody drug conjugate programs to expand its oncology pipeline.

  Item 8.01 verify on EDGAR →
• medium

  Hangzhou DAC presented data at ASCO Annual Meeting for DXC006, which uses the same CPT113 technology now accessible to Whitehawk, potentially validating the platform underlying the expanded pipeline.

  Item 8.01 verify on EDGAR →